TG Therapeutics, Inc. (TGTX) Stock Price & How to Invest
Last updated July 2026
Short answer
You can invest in TG Therapeutics (TGTX) by buying shares or fractional shares at any major US broker, through a biotech or healthcare ETF that holds it, or as one holding in a thematic basket. TG Therapeutics is a commercial-stage biopharmaceutical company built almost entirely around one product: BRIUMVI (ublituximab), an anti-CD20 monoclonal antibody approved for relapsing forms of multiple sclerosis. The core thesis is a single-drug growth story: BRIUMVI launched in 2023 and has scaled rapidly, pushing the company to sustained profitability, so the stock rises and falls mainly on how fast that one drug keeps taking share from larger rivals rather than on a diversified product line.
TGTX stock price
As of 2026-07-14, TG Therapeutics, Inc. (TGTX) last closed at $55.41, up 42.4% over the past year. Over the past 52 weeks it has traded between $26.39 and $59.06.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or TG Therapeutics, Inc.'s investor relations page. Walnut is informational, not investment advice.
What does TG Therapeutics, Inc. (TGTX) do?
TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company whose business is dominated by a single approved product: BRIUMVI (ublituximab), an anti-CD20 monoclonal antibody for relapsing forms of multiple sclerosis (MS). BRIUMVI launched commercially in the United States in early 2023 and has become one of the faster-growing MS therapies, competing against much larger anti-CD20 rivals. Because the company's revenue is concentrated in this one drug, its results and stock track BRIUMVI's prescription growth, pricing, and market-share gains far more than any broad pipeline.
The growth trajectory has been steep. BRIUMVI U.S. net product revenue was roughly $594 million for full-year 2025, about 92% above the prior year, and the company reported approximately $195 million in the first quarter of 2026 alone. Management raised full-year 2026 revenue guidance to roughly $885 to $900 million. Importantly, TG Therapeutics reached sustained profitability during 2025 after years of losses, a meaningful inflection for a single-product biotech. The pipeline story centers on extending BRIUMVI itself: a subcutaneous (under-the-skin) formulation of ublituximab in Phase 3 development and a consolidated dosing regimen being studied in the ENHANCE trial, both aimed at making the drug more convenient and defending its position as competition intensifies. The investment picture, then, is a fast-growing but highly concentrated franchise where the durability of BRIUMVI's momentum is the whole question.
What's driving TG Therapeutics, Inc. (TGTX)?
1. BRIUMVI revenue growth and share gains
The central driver is how fast BRIUMVI keeps growing. Revenue nearly doubled in 2025 and quarterly sales have continued to climb sharply into 2026, with management repeatedly raising guidance. New and total prescriptions have been tracking ahead of larger anti-CD20 competitors in recent quarters. As a near single-product company, TG Therapeutics lives and dies by whether that prescription momentum in MS holds up.
2. Swing to sustained profitability
After years of losses typical of a launch-stage biotech, TG Therapeutics reached profitability during 2025 and has strung together consecutive profitable quarters as BRIUMVI scaled past its fixed cost base. Operating leverage matters here: once launch costs are covered, incremental sales can drop toward the bottom line. Continued profitability would strengthen the balance sheet and reduce the need to raise capital.
3. Differentiated dosing and lifecycle expansion
BRIUMVI's pitch is a convenient twice-yearly, roughly one-hour maintenance infusion, a shorter administration than some rivals, backed by multi-year efficacy and safety data. The pipeline focuses on extending that edge: a subcutaneous (injectable) version in Phase 3 and a consolidated dosing schedule in the ENHANCE trial. Success on these could broaden the eligible patient base and defend share as competitors respond.
4. Large and durable MS market
Multiple sclerosis is a chronic, lifelong condition, and anti-CD20 therapies have become a leading class of treatment. That creates a large, recurring-revenue market with high patient retention once a therapy is started. TG Therapeutics is a smaller entrant taking share within that established category, so even modest continued penetration of a big market can support meaningful growth off its current base.
What are the risks to TG Therapeutics, Inc. (TGTX)?
The dominant risk is single-product concentration: with essentially all revenue from BRIUMVI, any slowdown in prescription growth, a pricing or reimbursement setback, or an unexpected safety signal would hit the whole company, unlike a diversified pharma. The anti-CD20 MS market is crowded and competitive, with far larger and better-resourced rivals such as Roche's Ocrevus and Novartis's Kesimpta, plus the potential for new entrants and generics or biosimilars over time. Pipeline execution is another risk: the subcutaneous formulation and consolidated dosing programs still need to succeed in Phase 3 and win regulatory approval, and clinical trials can fail. As a mid-cap biotech, the stock is volatile and sensitive to quarterly sales prints, guidance changes, and clinical news, so drawdowns can be sharp even when the long-term story is intact.
How is TG Therapeutics, Inc. (TGTX) valued? (approximate, Jul 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see TG Therapeutics, Inc.'s investor relations page or your broker.
- Revenue (TTM): Growing rapidly; BRIUMVI U.S. sales were ~$594M in FY2025 (up ~92% year over year), with 2026 guidance raised to ~$885-900M
- Profitability: Turned profitable in 2025 with several consecutive profitable quarters; a notable inflection for a single-product biotech
- Revenue concentration: Effectively all revenue from one drug, BRIUMVI, in multiple sclerosis
- Valuation multiple: Trades as a growth biotech; multiples reflect expected future BRIUMVI growth rather than current earnings, so they can look elevated
- Balance sheet: Improving as profitability funds operations; verify current cash and debt in the latest filing
- Analyst sentiment: Generally constructive on BRIUMVI momentum, though views vary on how durable the single-product growth is
These figures are approximate and tied to the asOf date; verify live numbers before acting. As a fast-growing, single-product biotech, TG Therapeutics is valued mostly on the expected future trajectory of one drug, so traditional earnings multiples matter less than the pace and durability of BRIUMVI's growth. Guidance has been raised repeatedly, but forward estimates are inherently uncertain and clinical or competitive setbacks could change the picture quickly.
Who competes with TG Therapeutics, Inc. (TGTX)?
Large anti-CD20 MS incumbents
BRIUMVI's most direct competitors are Roche's Ocrevus (ocrelizumab) and Novartis's Kesimpta (ofatumumab), the established anti-CD20 therapies for multiple sclerosis. Both come from far larger, better-capitalized companies with broad sales forces and deep pipelines. BRIUMVI competes on a differentiated, shorter twice-yearly infusion, but it is the smaller challenger taking share in a market these incumbents built.
Broader MS disease-modifying therapies
Beyond anti-CD20 drugs, MS patients and physicians can choose from other disease-modifying therapy classes, including oral therapies and other injectables from companies such as Biogen, Sanofi, and others. These alternatives shape prescribing decisions and pricing across the whole MS category, even where they are not directly comparable to BRIUMVI's mechanism.
Future biosimilars and new entrants
Over time, biosimilar versions of established anti-CD20 antibodies and novel MS mechanisms (for example BTK inhibitors in development at several large pharmas) could increase competition and pressure pricing. As a single-product company, TG Therapeutics is more exposed than diversified peers to any erosion from these longer-term competitive threats.
How to invest in TG Therapeutics, Inc. (TGTX)
There are three common ways to get TGTX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so TGTX sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where TGTX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on TG Therapeutics, Inc. (TGTX)
TG Therapeutics is a focused, single-product growth bet on BRIUMVI in multiple sclerosis. Rapid revenue growth and a recent swing to profitability are the draw, but concentration in one drug, a crowded anti-CD20 market, and pipeline execution are the risks. It suits growth-tolerant investors, not income seekers.
Build a basket around TGTX with Walnut
Use TG Therapeutics, Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is TGTX a good stock to buy right now?
+
That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is BRIUMVI's rapid revenue growth, repeated guidance raises, and a recent swing to sustained profitability. The bear case is that nearly all revenue comes from one drug in a crowded MS market with much larger rivals, which makes the stock volatile and concentrated. Weigh both against your own portfolio and consider consulting a licensed adviser.
What does TG Therapeutics actually do?
+
TG Therapeutics is a commercial-stage biopharmaceutical company focused on multiple sclerosis. Its business is built around one approved product, BRIUMVI (ublituximab), an anti-CD20 monoclonal antibody for relapsing forms of MS that launched in the US in 2023. The company develops, markets, and sells this drug, and its pipeline mainly aims to extend BRIUMVI with new formulations and dosing schedules.
Why is TGTX stock so volatile?
+
TGTX is a mid-cap biotech whose revenue comes almost entirely from a single drug, so its stock reacts sharply to each quarterly sales figure, guidance change, and clinical or competitive update. Single-product concentration means there is little to cushion any disappointment. Biotech stocks in general also carry regulatory and trial risk, which adds to price swings around news events.
Does TG Therapeutics pay a dividend?
+
No. Like most growth-stage biotech companies, TG Therapeutics does not pay a dividend and reinvests cash into commercializing BRIUMVI and advancing its pipeline. Investors buy it for potential share-price growth, not income. Always confirm the latest dividend policy in the company's current filings before assuming any payout.
What is BRIUMVI and why does it matter so much?
+
BRIUMVI (ublituximab) is TG Therapeutics' anti-CD20 monoclonal antibody approved for relapsing forms of multiple sclerosis, given as a twice-yearly, roughly one-hour maintenance infusion. It is effectively the company's only source of revenue, so BRIUMVI's growth, pricing, and market share drive the entire investment case. Understanding TGTX means understanding how BRIUMVI is doing.
Who does BRIUMVI compete against?
+
BRIUMVI competes mainly against other anti-CD20 MS therapies, especially Roche's Ocrevus and Novartis's Kesimpta, both from much larger companies. It also competes more broadly with other MS disease-modifying therapies, including oral options. BRIUMVI's differentiation is its shorter, twice-yearly infusion and multi-year safety and efficacy data, but the market is crowded and competitive.
How can I get exposure to TGTX through an ETF?
+
TGTX appears in many biotech, small- and mid-cap, and broad healthcare ETFs, where it sits among numerous drug-developer names. ETF exposure spreads single-stock risk across dozens of holdings but dilutes how much any TGTX move affects you. Always check a fund's holdings and weighting before assuming meaningful exposure to TG Therapeutics specifically.
What are the main risks of investing in TGTX?
+
The central risk is single-product concentration: almost all revenue comes from BRIUMVI, so any slowdown, pricing or reimbursement setback, or safety signal would hit the whole company. The anti-CD20 MS market is crowded with far larger rivals, pipeline programs still need to succeed in Phase 3, and biosimilars or new mechanisms could pressure the franchise over time. The stock is also volatile around quarterly results and clinical news.
Is TG Therapeutics profitable?
+
It became profitable during 2025 after years of losses, and has reported several consecutive profitable quarters as BRIUMVI sales scaled past the company's fixed cost base. That was a meaningful inflection for a single-product biotech. Profitability can still fluctuate with investment in the pipeline and sales growth, so check the latest results for the current picture.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with TG Therapeutics, Inc.'s investor relations page or your broker before making investment decisions.